vs
GENMAB A/S（GMAB）与PATTERSON UTI ENERGY INC（PTEN）财务数据对比。点击上方公司名可切换其他公司
PATTERSON UTI ENERGY INC的季度营收约是GENMAB A/S的1.2倍（$1.1B vs $925.0M），GENMAB A/S净利率更高（36.3% vs -2.2%，领先38.5%），GENMAB A/S同比增速更快（18.7% vs -12.7%）
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
帕特森UTI能源是领先的油田服务供应商，主营陆上合同钻井、压力泵送、完井及相关配套服务，核心市场覆盖北美地区，主要服务上游油气开采企业，业务聚焦页岩气、致密气等非常规资源开发领域。
GMAB vs PTEN — 直观对比
营收规模更大
PTEN
是对方的1.2倍
$925.0M
营收增速更快
GMAB
高出31.5%
-12.7%
净利率更高
GMAB
高出38.5%
-2.2%
损益表 — Q2 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $925.0M | $1.1B |
| 净利润 | $336.0M | $-24.5M |
| 毛利率 | 93.8% | — |
| 营业利润率 | 38.9% | — |
| 净利率 | 36.3% | -2.2% |
| 营收同比 | 18.7% | -12.7% |
| 净利润同比 | 65.5% | -166.1% |
| 每股收益（稀释后） | $5.42 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMABPTEN
| Q1 26 | — | $1.1B | ||
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | $925.0M | $1.2B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | $779.0M | $1.3B |
净利润GMABPTEN
| Q1 26 | — | $-24.5M | ||
| Q4 25 | — | $-9.2M | ||
| Q3 25 | — | $-36.4M | ||
| Q2 25 | $336.0M | $-49.1M | ||
| Q1 25 | — | $1.0M | ||
| Q4 24 | — | $-51.4M | ||
| Q3 24 | — | $-978.8M | ||
| Q2 24 | $203.0M | $11.1M |
毛利率GMABPTEN
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 93.8% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 96.4% | — |
营业利润率GMABPTEN
| Q1 26 | — | — | ||
| Q4 25 | — | -0.0% | ||
| Q3 25 | — | -2.4% | ||
| Q2 25 | 38.9% | -2.4% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | -2.7% | ||
| Q3 24 | — | -73.8% | ||
| Q2 24 | 30.3% | 3.4% |
净利率GMABPTEN
| Q1 26 | — | -2.2% | ||
| Q4 25 | — | -0.8% | ||
| Q3 25 | — | -3.1% | ||
| Q2 25 | 36.3% | -4.1% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | -4.5% | ||
| Q3 24 | — | -72.9% | ||
| Q2 24 | 26.1% | 0.8% |
每股收益（稀释后）GMABPTEN
| Q1 26 | — | $-0.06 | ||
| Q4 25 | — | $-0.01 | ||
| Q3 25 | — | $-0.10 | ||
| Q2 25 | $5.42 | $-0.13 | ||
| Q1 25 | — | $0.00 | ||
| Q4 24 | — | $-0.10 | ||
| Q3 24 | — | $-2.50 | ||
| Q2 24 | $3.13 | $0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.3B | $3.2B |
| 总资产 | $6.5B | $5.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GMABPTEN
| Q1 26 | — | — | ||
| Q4 25 | — | $418.5M | ||
| Q3 25 | — | $184.8M | ||
| Q2 25 | $1.3B | $183.8M | ||
| Q1 25 | — | $223.1M | ||
| Q4 24 | — | $239.2M | ||
| Q3 24 | — | $113.4M | ||
| Q2 24 | $622.0M | $72.4M |
总债务GMABPTEN
| Q1 26 | — | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B |
股东权益GMABPTEN
| Q1 26 | — | $3.2B | ||
| Q4 25 | — | $3.2B | ||
| Q3 25 | — | $3.2B | ||
| Q2 25 | $5.3B | $3.3B | ||
| Q1 25 | — | $3.4B | ||
| Q4 24 | — | $3.5B | ||
| Q3 24 | — | $3.6B | ||
| Q2 24 | $4.4B | $4.6B |
总资产GMABPTEN
| Q1 26 | — | $5.4B | ||
| Q4 25 | — | $5.6B | ||
| Q3 25 | — | $5.5B | ||
| Q2 25 | $6.5B | $5.6B | ||
| Q1 25 | — | $5.8B | ||
| Q4 24 | — | $5.8B | ||
| Q3 24 | — | $6.0B | ||
| Q2 24 | $5.6B | $7.0B |
负债/权益比GMABPTEN
| Q1 26 | — | — | ||
| Q4 25 | — | 0.38× | ||
| Q3 25 | — | 0.38× | ||
| Q2 25 | — | 0.37× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | — | 0.36× | ||
| Q3 24 | — | 0.35× | ||
| Q2 24 | — | 0.27× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $349.0M | $63.9M |
| 自由现金流经营现金流 - 资本支出 | $327.0M | — |
| 自由现金流率自由现金流/营收 | 35.4% | — |
| 资本支出强度资本支出/营收 | 2.4% | 4.9% |
| 现金转化率经营现金流/净利润 | 1.04× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流GMABPTEN
| Q1 26 | — | $63.9M | ||
| Q4 25 | — | $397.5M | ||
| Q3 25 | — | $215.8M | ||
| Q2 25 | $349.0M | $139.7M | ||
| Q1 25 | — | $208.1M | ||
| Q4 24 | — | $315.8M | ||
| Q3 24 | — | $296.3M | ||
| Q2 24 | $438.0M | $197.5M |
自由现金流GMABPTEN
| Q1 26 | — | — | ||
| Q4 25 | — | $259.0M | ||
| Q3 25 | — | $71.3M | ||
| Q2 25 | $327.0M | $-4.5M | ||
| Q1 25 | — | $46.3M | ||
| Q4 24 | — | $175.5M | ||
| Q3 24 | — | $115.7M | ||
| Q2 24 | $430.0M | $67.0M |
自由现金流率GMABPTEN
| Q1 26 | — | — | ||
| Q4 25 | — | 22.6% | ||
| Q3 25 | — | 6.1% | ||
| Q2 25 | 35.4% | -0.4% | ||
| Q1 25 | — | 3.7% | ||
| Q4 24 | — | 15.3% | ||
| Q3 24 | — | 8.6% | ||
| Q2 24 | 55.2% | 5.0% |
资本支出强度GMABPTEN
| Q1 26 | — | 4.9% | ||
| Q4 25 | — | 12.1% | ||
| Q3 25 | — | 12.3% | ||
| Q2 25 | 2.4% | 11.9% | ||
| Q1 25 | — | 12.8% | ||
| Q4 24 | — | 12.2% | ||
| Q3 24 | — | 13.5% | ||
| Q2 24 | 1.0% | 9.8% |
现金转化率GMABPTEN
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.04× | — | ||
| Q1 25 | — | 207.11× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.16× | 17.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
PTEN
暂无分部数据
